Newsmeme!
Discover News you didn't know existed
Dutton Associates updates its coverage of Vyteris (OTCBB:VYTR) maintaining a Speculative Buy rating and a $1 price target. The 13-page report by Dutton senior analyst Richard W. West, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg Professional, FactSet, Capital IQ, Zacks, Reuters, Knobias, and other leading financial portals.
Oncolytics Biotech Inc. announced today that that it has started patient enrolment in a Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers.
FARMINGTON — San Juan Regional Medical Center is one of six hospitals statewide that are participating in the state Department of Health's healthcare-associated infection pilot project.
ROSEVILLE, Calif.----Dutton Associates updates its coverage of Vyteris maintaining a Speculative Buy rating and a $1 price target. The 13-page report by Dutton senior analyst Richard W.
TopoTarget A/S (OMX: TOPO) announced that a positive reply from the FDA was received on a Special Protocol Assessment (SPA) for a phase III trial for belinostat in PTCL (Peripheral T-Celle Lymphoma). This pivotal trial is to enrol approximately 120 patients and is to begin in Q4 2008.
CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced Phase II results of its lead compound COL-144 in the treatment of acute migraine. Results demonstrated that COL-144 was safe and effective in relieving migraine headaches.
A third of patients have unnecessary tubes (cannulae) inserted when they are in hospital, needlessly exposing them to serious complications such as infection and blood clots, research launched at the British Pharmaceutical Conference (BPC) in Manchester has shown.
An effective new method of diagnosing bowel (also known as colorectal, or large bowel) cancer using 'light' may soon be available, according to research presented at the British Pharmaceutical Conference (BPC) in Manchester.
SAN FRANCISCO----Five Prime Therapeutics, Inc. today announced the first patient has been enrolled in a Phase I clinical trial of its investigational protein therapeutic, FP-1039, in patients with advanced solid tumors.
Mo Twister finally speaks up about his daughter's true condition, dismissing reports that his daughter with Bunny Paras, Moira, has brain cancer. Interviewed by Showbiz Central co-host Pia Guanio yesterday, September 7, Mo expressed mixed emotions of disappointment, hope, and joy.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |